Vistagen on track to deliver topline data from fasedienol palisade-3 phase 3 trial for acute treatment of social anxiety disorder in the fourth quarter of this year

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today provides an update on the timeline for the ongoing clinical trials in its u.s. registration-directed palisade phase 3 program evaluating fasedienol for acute treatment of social anxiety disorder (sad). the company's palisade-.
VTGN Ratings Summary
VTGN Quant Ranking